Stockscreener 앱 받기
0.3715
3.00%
-0.0115
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Is Plus Therapeutics Inc. a good long term investmentUnstoppable investment returns - Jammu Links News
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq
Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - Yahoo Finance
Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study - TipRanks
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire
Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference | PSTV Stock News - GuruFocus
Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq
Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan
Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa
Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire
Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus
Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener
Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan
Plus Therapeutics Soars 49.17% on Promising Brain Cancer Trial Results - AInvest
Plus Therapeutics shares fall 3.72% premarket after FDA clearance of Reyobiq for childhood brain cancer. - AInvest
Plus Therapeutics, Inc. shares fall 1.63% premarket after Novartis' Cosentyx fails in Phase III GCAptAIN study. - AInvest
Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest
Plus Therapeutics shares rise 10.48% intraday after FDA agreement to initiate ReSPECT-LM dose optimization trial. - AInvest
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Plus Therapeutics (PSTV) Maintains Buy Rating Despite Price Target Cut | PSTV Stock News - GuruFocus
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary | PSTV Stock News - GuruFocus
Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus
PSTV Stock Update: D. Boral Capital Maintains Hold Rating for Plus Therapeutics | PSTV Stock News - GuruFocus
Plus Therapeutics: A Cancer-Fighting Catalyst on Tap – Here's Why June 26 Could Be a Breakout Day for PSTV - AInvest
Plus Therapeutics (PSTV) Restructures $15M Equity Financing to Minimize Dilution | PSTV Stock News - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus (PSTV) Upgraded to Buy: Here's Why - Nasdaq
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | PSTV Stock News - GuruFocus
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Plus Therapeutics Plunges 10.89% Amid Institutional Shifts - AInvest
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss - AInvest
Why Did Plus Therapeutics (PSTV) Soar 36.24% Pre-Market After Earnings Miss? - AInvest
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
0.59%
0.34%
자본화:
|
볼륨(24시간):